Experience with Tirzepatide and Weight Management During and After a Clinical Trial in Japanese Patients with Obesity Disease: A Qualitative Study Authors: Arihiro Kiyosue, Manaka Sato, Zhihong Cai, Yasushi Fukushima, Masahiko Takai, Toshiyuki Takahashi, Hirotaka Nagashima, Shintaro Suo, Ryohei Takeda, Kanako Shimoura, Tomotaka Shingaki Published: 2026 ABSTRACT IntroductionThe phase 3 SURMOUNT-J clinical trial showed that Japanese adults with obesity disease achieved clinically meaningful body weight loss with once-weekly tirzepatide for 72 weeks. The primary objective of the present study was to explore participants’ experiences with tirzepatide during SURMOUNT-J and body weight changes after the trial. Secondary objectives were to explore participant experiences with other weight loss treatments and body weight management after the trial, and to understand the healthcare provider support needs related to obesity disease treatment.MethodsThis was a cross-sectional, non-interventional, semi-structured, qualitative exit interview study conducted in Japan. Tirzepatide-treated participants in SURMOUNT-J who completed the 72-week study were recruited for this study. Participants completed a web-based interview about their experience during and after SURMOUNT-J.ResultsTwenty-nine participants completed the interviews. During SURMOUNT-J, 75.9% of participants experienced appetite loss, 72.4% experienced conscious eating habit changes, 62.1% had positive feelings associated with body weight loss, and 75.9% expressed willingness to continue drug therapy. Additionally, 58.6% experienced joy being able to choose new clothes, and 51.7% experienced lighter body movements. After SURMOUNT-J ended, 51.7% of participants maintained their changes in eating behavior, 44.8% were not able to maintain their changes in exercise/physical activity, and 65.5% experienced poor appetite control. The interviews revealed a potential unmet need to provide information to people with obesity disease and to connect them with appropriate medical interventions.ConclusionsStudy participants who received tirzepatide treatment reported that they were able to maintain their changes in eating behaviors but not exercise habits after SURMOUNT-J. Three-quarters of participants expressed a desire to continue drug therapy for obesity disease treatment.Supplementary InformationThe online version contains supplementary material available at 10.1007/s12325-026-03660-x. Key Summary Points Why carry out this study? The phase 3 SURMOUNT-J clinical trial demonstrated that Japanese adults with obesity disease achieved clinically meaningful body weight loss through the administration of tirzepatide for 72 weeks.This study aimed to explore participants’ experiences with tirzepatide during SURMOUNT-J, as well as body weight changes, other weight loss treatments, and body weight management after the trial. What was learned from the study? Participants reported that changes in eating behaviors acquired during SURMOUNT-J were retained after stopping tirzepatide but not changes in exercise behaviors; approximately three-quarters of participants expressed a desire to continue drug therapy for obesity disease treatment.Providing information to people with obesity disease and connecting them with appropriate medical interventions are essential. Why carry out this study? The phase 3 SURMOUNT-J clinical trial demonstrated that Japanese adults with obesity disease achieved clinically meaningful body weight loss through the administration of tirzepatide for 72 weeks.This study aimed to explore participants’ experiences with tirzepatide during SURMOUNT-J, as well as body weight changes, other weight loss treatments, and body weight management after the trial. What was learned from the study? Participants reported that changes in eating behaviors acquired during SURMOUNT-J were retained after stopping tirzepatide but not changes in exercise behaviors; approximately three-quarters of participants expressed a desire to continue drug therapy for obesity disease treatment.Providing information to people with obesity disease and connecting them with appropriate medical interventions are essential. Introduction Obesity-related health disorders (e.g., hypertension, dyslipidemia, glucose tolerance disorder) often occur at a lower body mass index (BMI) in Japanese people than those from Western countries (≥ 25 kg/m2 vs. ≥ 30 kg/m2) [1]. On the basis of this, the Japan Society for the Study of Obesity have advocated the concept of “obesity disease,” which uses a BMI threshold of ≥ 25 kg/m2 to define obesity disease, rather than the ≥ 30 kg/m2 threshold for obesity used in the rest of the world [1, 2]. People with a high BMI (≥ 25 kg/m2) and with either certain obesity-related health disorders or an accumulation of visceral fat are diagnosed with obesity disease in Japan [1, 3, 4]. The diagnostic criteria comprise 11 obesity-related health disorders, including glucose tolerance disorders (type 2 diabetes and impaired glucose tolerance), dyslipidemia, and hypertension [1], all of which are associated with an increased incidence of cardiometabolic disease and an increased risk of premature death [5–8]. Obesity disease is also associated with an increased risk of several cancers and has been identified as a public health concern [9]. The global prevalence of obesity (defined as a BMI ≥ 30 kg/m2) among adults was 16% in 2022 [10]. The prevalence varies by geographical region, with the Americas and Europe having the highest rates [11]. The number of adults living with obesity is expected to further increase over time [12]. Non-alcoholic fatty liver disease (NAFLD), which increases the risk of liver-related and cardiovascular-related morbidity and mortality, is relatively common in people with obesity, and studies have shown that body weight loss can improve markers of liver disease in patients with the condition [13]. Among adults in Japan, 31.5% of men and 21.1% of women have a BMI ≥ 25 kg/m2 [14]; the proportion of people with a BMI ≥ 25 kg/m2 has been trending upward since the 1970s [15, 16]. Obesity disease-related cardiovascular risk factors can be reduced with a loss of 5–10% of body weight through lifestyle approaches such as caloric restriction, increased physical activity, and behavioral therapy [17, 18]. Such approaches may also improve health-related quality of life [19]. Unfortunately, lifestyle approaches alone fail to achieve sustainable body weight loss in most individuals with obesity disease [20]. Pharmacological interventions are available for people with obesity disease; however, they are only indicated in people for whom changes in diet, exercise, and behavioral therapy are inadequate [1]. Currently available pharmacotherapies include glucagon-like peptide 1 (GLP-1) receptor agonists, which are used to treat diabetes and have been shown to reduce body weight [21]. Tirzepatide is a dual GLP-1 and glucose-dependent insulinotropic polypeptide receptor agonist [22]. It is a once-weekly subcutaneous injectable drug that has been shown to induce substantial and sustained body weight loss in adults with obesity or overweight [23]. The SURMOUNT-J clinical trial (SURMOUNT-J) was a phase 3 trial of the efficacy and safety of tirzepatide (10 mg or 15 mg) versus placebo on a background of a reduced-calorie diet and increased physical activity in Japanese adults with obesity disease [24]. The trial demonstrated a clinically meaningful body weight loss with once-weekly tirzepatide for 72 weeks [24]. Over 94% of participants who received tirzepatide achieved ≥ 5% body weight reduction and over half achieved ≥ 20% body weight reduction from baseline to week 72. There were also improvements in body composition, metabolic and glycemic parameters, obesity-related health disorders, hepatic factors, cardiometabolic risk factors, and patient-reported outcomes with tirzepatide treatment. While SURMOUNT-J provided quantitative data demonstrating the efficacy, safety, and patient-reported outcomes of tirzepatide, qualitative assessments of participants’ subjective experiences during and after the trial have not been performed. The primary objective of the present study was to explore participant experiences with tirzepatide as a treatment for obesity disease in SURMOUNT-J and body weight changes after the trial [24]. Secondary objectives were to explore participant experiences with both other treatments and body weight management after SURMOUNT-J, and to understand what healthcare provider support participants desire for their treatment of obesity disease. While a similar study was conducted with participants in the SURMOUNT-4 clinical trial in the USA [25], the present study represents the first such study in the Japanese population. Methods Study Design and Setting This was a cross-sectional, non-interventional, semi-structured, qualitative exit interview study conducted in Japan from August 2024 through October 2024. Patients who were assigned to the tirzepatide treatment group in SURMOUNT-J were identified by the principal investigators at each study site using patient medical records [24]. Potential participants were then recruited to the present study at outpatient visits, by email or messenger applications (e.g., LINE smartphone app), or by telephone. Each potential participant was provided with a two-dimensional code to initiate their participation in the study. After participants were recruited to the study and responded to screening questions, they were asked to provide electronic informed consent. Physicians confirmed participant eligibility based on the information in their medical records and their responses to the screening questions. Before the interview was conducted, participants completed a questionnaire, in which they provided information related to body weight, treatment history of obesity disease, and their participation in clinical trials other than SURMOUNT-J. Additionally, they completed a pre-survey (Supplementary Fig. S1), which was not for collecting data but rather served to provide information on each participant’s journey to support the interview process. The pre-survey was designed to take approximately 20 min to complete and was conducted to mitigate recall bias. Other background data were collected from each participant’s medical record. Participants then scheduled an online interview (Supplementary Text S1), which was expected to take approximately 60 min to complete and was conducted using a web-based conferencing system. Interviews were conducted by an experienced interviewer who was not an author of the present manuscript, was female, and was a moderator and medical writer at the time the study was conducted. She did not have any prior relationship with the study participants and had performed 420 medical-related interviews since 2020, 40 of which were related to obesity or lifestyle disease. The participants did not have any prior knowledge of the interviewer. All interviews were recorded and transcribed by 3H (3H Clinical Trial Inc., Tokyo, Japan). The transcripts were not returned to the participants for comment or correction. The interviews included five sections, with each section comprising two to five main questions and taking 5–15 min to complete. Anonymized data and interview transcripts were provided to Mebix Inc. (Tokyo, Japan), which performed qualitative analysis of the information. Three coders participated in the analysis. Participants did not provide feedback on the study findings. The study was reported in accordance with the COREQ guidelines. Participants Although six study sites were initially scheduled to participate, one study site was excluded because of a regulatory non-compliance issue, resulting in five study sites being included in this interview study. Participants who met the following inclusion criteria were eligible for enrollment: assigned to the active treatment group in SURMOUNT-J, and completed the 72-week SURMOUNT-J study (N = 125), and were within 24 months of completing the active drug group requirements in SURMOUNT-J [24]. Participants were excluded from the study if they met any of the following exclusion criteria: history of malignancy or thyroid disease between the end of SURMOUNT-J and their participation in the study pre-survey, or used tirzepatide after completion of SURMOUNT-J. The study protocol was approved by the Takahashi Clinic Ethics Committee (LNW00210); this approval covered the necessary ethics approvals for all five study sites. The study was conducted in accordance with the ethical principles described in the Declaration of Helsinki, the Ethical Guidelines for Medical and Biological Research Involving Human Subjects, and all applicable Japanese laws and regulations. All participants provided electronic informed consent to participate in the study and to publish the verbatim responses from the study. SURMOUNT-J [24] is registered at ClinicalTrials.gov (NCT04844918). Data Collection Participant background data at the time of enrollment in SURMOUNT-J, as well as body weight following completion of SURMOUNT-J, were collected from study site medical records and transcribed to the electronic data capture system of SURMOUNT-J [24]. Background data (body weight, treatment history of obesity disease, and information about participation in clinical trials other than SURMOUNT-J) at the time of enrollment in the present study were self-reported by participants. Participant interviews were conducted to collect information related to the following topics: experience related to tirzepatide treatment during SURMOUNT-J, experience with other treatments and body weight management after completion of SURMOUNT-J, experience with body weight change after SURMOUNT-J, healthcare provider support sought by participants, and the psychological burden experienced with tirzepatide injections. Participant narratives included in the text and Supplementary File 3 are not comprehensive but provide narratives that are representative of each interview section. Data Analysis The target sample size was set to 30 participants, based on the number of participants in SURMOUNT-J [24] who were able to access the present study. Categorical variables are summarized using frequency and proportion, while continuous variables are summarized with descriptive statistics. Content analysis was conducted on the interview data and transcripts using NVivo software (QSR International Pty Ltd., Doncaster, Australia). The analysis was conducted in an inductive manner. To enhance the credibility of the qualitative findings, the analyses were conducted using triangulation, where a researcher other than the analyst or a third party confirmed the interpretation of results. A coding tree was also created in NVivo software to ensure transparency in the analysis process. Discrepancies among the three coders were resolved through discussion and consensus. Sex/gender analysis was not conducted as qualitative research typically involves small sample sizes, making analysis by sex/gender prone to overgeneralization. Furthermore, this study aimed to understand how participants interpret their experiences as a whole; thus, it focused on common patterns rather than differences by sex or gender. Results Participants Thirty-two individuals provided informed consent to participate in the study. Of those, one participant withdrew consent, and two participants were lost to follow-up. In total, 29 participants completed the interviews, which represented 23.2% of patients in the active treatment group (N = 125) of SURMOUNT-J. Participant background characteristics are shown in Table 1. At SURMOUNT-J enrollment, the mean ± standard deviation (SD) age and body weight among the 29 participants were 45.8 ± 9.8 years and 92.1 ± 15.8 kg, respectively. The mean ± SD body weight was 76.8 ± 16.7 kg at the end of the trial and 84.4 ± 19.2 kg at the time of enrollment in the present study. The most common obesity-related health issues were dyslipidemia (93.1%), hypertension (48.3%), hyperuricemia and/or gout (34.5%), and NAFLD (31.0%). Most participants (75.9%) did not participate in another clinical trial after completing SURMOUNT-J. The mean ± SD (range, interquartile range) number of days from the last tirzepatide dose to the study interview was 617.8 ± 59.6 (507–715, 577.0–683.0) days and there was a mean ± SD weight change of 7.59 ± 6.65 kg from the end of SURMOUNT-J to enrollment in the present study. SURMOUNT-J concluded in June 2023, and the first participant was enrolled in the present study in August 2024. Supplementary Table S2 presents baseline demographic data for the active treatment group in SURMOUNT-J and the participants enrolled in the present study.Table 1Participant background characteristicsStudy participants (N = 29)Sex Male15 (51.7) Female14 (48.3)Age at SURMOUNT-J enrollment, years45.8 ± 9.8Body weight at SURMOUNT-J enrollment, kg92.1 ± 15.8Body weight at the end of SURMOUNT-J, kg76.8 ± 16.7BMI at SURMOUNT-J enrollment, kg/m233.9 ± 4.5BMI at the end of SURMOUNT-J, kg/m228.2 ± 5.1History of smoking at SURMOUNT-J enrollment Regular3 (10.3) Occasional0 (0.0) Never24 (82.8) No response2 (6.9)History of alcohol use at SURMOUNT-J enrollment Regular15 (51.7) Occasional5 (17.2) Never9 (31.0) No response0 (0.0)Obesity-related health issues at SURMOUNT-J enrollment Dyslipidemia27 (93.1) Hypertension14 (48.3) Hyperuricemia and/or gout10 (34.5) Non-alcoholic fatty liver disease9 (31.0) Glucose intolerance disorder (IGT, others)4 (13.8) Menstruation disorders and/or infertility (female participants only; n = 14)1 (7.1) Cardiovascular disease, myocardial infarction, and/or angina1 (3.4) Obstructive sleep apnea syndrome and/or obesity disease-hypoventilation syndrome1 (3.4) Arthritis/osteoarthritis (knee, hip joint, spine, etc.)1 (3.4) Obesity-related renal disease1 (3.4) Cerebral infarction and/or transient ischemic attack0Participation in other clinical trials after completing SURMOUNT-J Participated/currently participating7 (24.1) Did not participate/not currently participating22 (75.9) Body weight at the time of present study enrollment, kg84.4 ± 19.2 Body weight change from the end of SURMOUNT-J to enrollment in the present study,akg7.59 ± 6.65 BMI at the time of present study enrollment,b kg/m231.0 ± 6.0Duration from last tirzepatide dose to interview, days (range, interquartile range)617.8 ± 59.6 (507–715, 577.0–683.0)Data are presented as n (%) or mean ± standard deviationIGT impaired glucose tolerance, BMI body mass indexaCalculated from body weight at end of SURMOUNT-J trial and patient-reported body weight at the time of present study enrollmentbCalculated by height at SURMOUNT-J trial enrollment and patient-reported body weight at the time of present study enrollment Table 1Participant background characteristicsStudy participants (N = 29)Sex Male15 (51.7) Female14 (48.3)Age at SURMOUNT-J enrollment, years45.8 ± 9.8Body weight at SURMOUNT-J enrollment, kg92.1 ± 15.8Body weight at the end of SURMOUNT-J, kg76.8 ± 16.7BMI at SURMOUNT-J enrollment, kg/m233.9 ± 4.5BMI at the end of SURMOUNT-J, kg/m228.2 ± 5.1History of smoking at SURMOUNT-J enrollment Regular3 (10.3) Occasional0 (0.0) Never24 (82.8) No response2 (6.9)History of alcohol use at SURMOUNT-J enrollment Regular15 (51.7) Occasional5 (17.2) Never9 (31.0) No response0 (0.0)Obesity-related health issues at SURMOUNT-J enrollment Dyslipidemia27 (93.1) Hypertension14 (48.3) Hyperuricemia and/or gout10 (34.5) Non-alcoholic fatty liver disease9 (31.0) Glucose intolerance disorder (IGT, others)4 (13.8) Menstruation disorders and/or infertility (female participants only; n = 14)1 (7.1) Cardiovascular disease, myocardial infarction, and/or angina1 (3.4) Obstructive sleep apnea syndrome and/or obesity disease-hypoventilation syndrome1 (3.4) Arthritis/osteoarthritis (knee, hip joint, spine, etc.)1 (3.4) Obesity-related renal disease1 (3.4) Cerebral infarction and/or transient ischemic attack0Participation in other clinical trials after completing SURMOUNT-J Participated/currently participating7 (24.1) Did not participate/not currently participating22 (75.9) Body weight at the time of present study enrollment, kg84.4 ± 19.2 Body weight change from the end of SURMOUNT-J to enrollment in the present study,akg7.59 ± 6.65 BMI at the time of present study enrollment,b kg/m231.0 ± 6.0Duration from last tirzepatide dose to interview, days (range, interquartile range)617.8 ± 59.6 (507–715, 577.0–683.0)Data are presented as n (%) or mean ± standard deviationIGT impaired glucose tolerance, BMI body mass indexaCalculated from body weight at end of SURMOUNT-J trial and patient-reported body weight at the time of present study enrollmentbCalculated by height at SURMOUNT-J trial enrollment and patient-reported body weight at the time of present study enrollment Participant background characteristics Data are presented as n (%) or mean ± standard deviation IGT impaired glucose tolerance, BMI body mass index aCalculated from body weight at end of SURMOUNT-J trial and patient-reported body weight at the time of present study enrollment bCalculated by height at SURMOUNT-J trial enrollment and patient-reported body weight at the time of present study enrollment Participant Experiences During SURMOUNT-J Over half of participants reported experiencing appetite loss (75.9%), conscious changes in eating habits (72.4%), positive feelings associated with body weight loss (62.1%), joy of being able to choose clothes (58.6%), and lighter body movements (51.7%) during SURMOUNT-J (Table 2). Representative patient narratives related to this topic are presented below and in Supplementary Table S1.“I feel full very quickly now. […] I finish without getting an extra serving of noodles even when I have pork bone-based ramen. The portion of the ramen is small to begin with. But that is how I felt. […] (Having an extra serving of noodles before the trial) was just normal for me. Well, I used to be done with just one extra serving anyway.” [Appetite loss due to tirzepatide efficacy, Male, 50s].“(Changes in eating habits after losing weight during the clinical trial) I shifted from buying, eating, and drinking whatever I liked to being more mindful of ingredients and choosing healthier options. I used to select things based on price, but now I look at the ingredients rather than the cost. I have become more conscious of my choices. That said, I am not very knowledgeable, so I cannot control my calorie intake precisely. However, I have started choosing options that seem better. I no longer eat impulsively. Instead, I think about whether I actually need it at that moment. I have started pausing for a moment before meals.” [Conscious changes in eating habits, Female, 50s].“I used to consume excess amounts of carbohydrates and oily foods. I tried to cut back on those foods as much as possible and made an effort to eat more vegetables, yogurt, and soy-based products.” [Conscious changes in eating habits, Female, 40s].Table 2Themes of experiences during SURMOUNT-JStudy participants (N = 29)Appetite loss due to tirzepatide efficacy22 (75.9)Conscious changes in eating habits21 (72.4)Positive feelings associated with body weight loss18 (62.1)Joy of being able to choose clothes17 (58.6)Lighter body movements15 (51.7)Improvement in laboratory data13 (44.8)Adverse events12 (41.4)Changes in exercise habits11 (37.9)Positive reaction from others10 (34.5)Gained confidence because of a better appearance7 (24.1)Alleviation of lower back and joint pain6 (20.7)Decreased physical strength4 (13.8)Improved sleep quality3 (10.3)Loss of joy in eating3 (10.3)Data are presented as n (%) “I feel full very quickly now. […] I finish without getting an extra serving of noodles even when I have pork bone-based ramen. The portion of the ramen is small to begin with. But that is how I felt. […] (Having an extra serving of noodles before the trial) was just normal for me. Well, I used to be done with just one extra serving anyway.” [Appetite loss due to tirzepatide efficacy, Male, 50s]. “(Changes in eating habits after losing weight during the clinical trial) I shifted from buying, eating, and drinking whatever I liked to being more mindful of ingredients and choosing healthier options. I used to select things based on price, but now I look at the ingredients rather than the cost. I have become more conscious of my choices. That said, I am not very knowledgeable, so I cannot control my calorie intake precisely. However, I have started choosing options that seem better. I no longer eat impulsively. Instead, I think about whether I actually need it at that moment. I have started pausing for a moment before meals.” [Conscious changes in eating habits, Female, 50s]. “I used to consume excess amounts of carbohydrates and oily foods. I tried to cut back on those foods as much as possible and made an effort to eat more vegetables, yogurt, and soy-based products.” [Conscious changes in eating habits, Female, 40s]. Table 2Themes of experiences during SURMOUNT-JStudy participants (N = 29)Appetite loss due to tirzepatide efficacy22 (75.9)Conscious changes in eating habits21 (72.4)Positive feelings associated with body weight loss18 (62.1)Joy of being able to choose clothes17 (58.6)Lighter body movements15 (51.7)Improvement in laboratory data13 (44.8)Adverse events12 (41.4)Changes in exercise habits11 (37.9)Positive reaction from others10 (34.5)Gained confidence because of a better appearance7 (24.1)Alleviation of lower back and joint pain6 (20.7)Decreased physical strength4 (13.8)Improved sleep quality3 (10.3)Loss of joy in eating3 (10.3)Data are presented as n (%) Themes of experiences during SURMOUNT-J Data are presented as n (%) Laboratory data improvements, adverse events, changes in exercise habits, positive reaction from others, gain in confidence because of better appearance, and alleviation of lower back and joint pain were experienced by 44.8%, 41.4%, 37.9%, 34.5%, 24.1%, and 20.7% of participants, respectively. Less than 15% of participants experienced decreased physical strength (13.8%), improved sleep quality (10.3%), and loss of joy in eating (10.3%). Participant Experiences After Completing SURMOUNT-J After completing SURMOUNT-J, just over half of the participants maintained their changes in eating behavior (51.7%). In contrast, 44.8% of participants were unable to maintain their changes in exercise and 65.5% of participants experienced poor appetite control (Table 3). Representative patient narratives related to this topic are presented below and in Supplementary Table S1.“Yes. I like to think that I am living a pretty healthy lifestyle now. […] I have started feeling like I just cannot eat ramen anymore (laughs). […] My food preferences have changed a lot. […] I cannot even eat fried chicken anymore. […] I could not tolerate greasy foods during the trial and felt like they were ‘too much.’ But oily ramen makes me feel nauseous, even after the trial ended, maybe because of my age. I just cannot eat it anymore.” [Maintenance of eating behavior changes, Male, 40s].“Yeah, I have changed. I no longer eat mindlessly—I have become more aware of portion sizes as I eat. I also focus on having vegetable-based side dishes and try to keep staples and meat portions smaller. Moreover, I think that my cooking patterns have changed a bit too.” [Maintenance of eating behavior changes, Female, 70s].Table 3Themes of experiences after completing SURMOUNT-JStudy participants (N = 29)Poor appetite control19 (65.5)Maintenance of eating behavior changes15 (51.7)Failure to maintain exercise habits13 (44.8)Negative feelings associated with regaining body weight9 (31.0)Habitual body weight measurement6 (20.7)Alternative behaviors to prevent regaining body weight4 (13.8)Recurrence of joint pain3 (10.3)Data are presented as n (%) “Yes. I like to think that I am living a pretty healthy lifestyle now. […] I have started feeling like I just cannot eat ramen anymore (laughs). […] My food preferences have changed a lot. […] I cannot even eat fried chicken anymore. […] I could not tolerate greasy foods during the trial and felt like they were ‘too much.’ But oily ramen makes me feel nauseous, even after the trial ended, maybe because of my age. I just cannot eat it anymore.” [Maintenance of eating behavior changes, Male, 40s]. “Yeah, I have changed. I no longer eat mindlessly—I have become more aware of portion sizes as I eat. I also focus on having vegetable-based side dishes and try to keep staples and meat portions smaller. Moreover, I think that my cooking patterns have changed a bit too.” [Maintenance of eating behavior changes, Female, 70s]. Table 3Themes of experiences after completing SURMOUNT-JStudy participants (N = 29)Poor appetite control19 (65.5)Maintenance of eating behavior changes15 (51.7)Failure to maintain exercise habits13 (44.8)Negative feelings associated with regaining body weight9 (31.0)Habitual body weight measurement6 (20.7)Alternative behaviors to prevent regaining body weight4 (13.8)Recurrence of joint pain3 (10.3)Data are presented as n (%) Themes of experiences after completing SURMOUNT-J Data are presented as n (%) Negative feelings associated with body weight gain were reported by 31.0% of participants; 20.7% reported habitual body weight management; 13.8% reported alternative behaviors to prevent regaining body weight; and 10.3% experienced recurrence of joint pain.“I am going to a beauty clinic now. Yes. I feel like spending money is my only option (laughs). I do not really know how to lose weight on my own anymore, and it does not look like my metabolism is improving as I get older. That is why.” [Alternative behaviors to prevent regaining body weight, Male, 50s]. “I am going to a beauty clinic now. Yes. I feel like spending money is my only option (laughs). I do not really know how to lose weight on my own anymore, and it does not look like my metabolism is improving as I get older. That is why.” [Alternative behaviors to prevent regaining body weight, Male, 50s]. Obesity Management Needs Most participants expressed a willingness to continue drug therapy and desired personalized diet and exercise therapy (75.9% and 72.4%, respectively) (Table 4). Just under half of the participants wanted to be monitored by healthcare providers (44.8%), and 41.4% of participants needed treatment without worrying about how they appeared to others. Affordable treatment under insurance coverage and easy access to healthcare were desired by 37.9% of participants each. Positive feedback from healthcare providers, provision of information regarding obesity-related risks, and information on departments offering obesity treatment were desired by 31.0%, 13.8%, and 10.3% of participants, respectively.Table 4Themes of obesity management needsStudy participants (N = 29)Willingness to continue drug therapy22 (75.9)Personalized diet and exercise therapy21 (72.4)Monitoring by healthcare providers13 (44.8)Needed treatment without worrying about how they appeared to others12 (41.4)Affordable treatment under insurance coverage11 (37.9)Easy access to healthcare11 (37.9)Positive feedback from healthcare providers9 (31.0)Provision of information regarding obesity-related risks4 (13.8)Seeking information on departments offering treatment for obesity3 (10.3)Data are presented as n (%) Table 4Themes of obesity management needsStudy participants (N = 29)Willingness to continue drug therapy22 (75.9)Personalized diet and exercise therapy21 (72.4)Monitoring by healthcare providers13 (44.8)Needed treatment without worrying about how they appeared to others12 (41.4)Affordable treatment under insurance coverage11 (37.9)Easy access to healthcare11 (37.9)Positive feedback from healthcare providers9 (31.0)Provision of information regarding obesity-related risks4 (13.8)Seeking information on departments offering treatment for obesity3 (10.3)Data are presented as n (%) Themes of obesity management needs Data are presented as n (%) Participant Experience with the Tirzepatide Injection Device Five categories related to the tirzepatide injection device were extracted. Most participants reported that the device was convenient and easy to use and that resistance to injection was quickly resolved (72.4% for each). Over half of the participants reported that they had difficulties with the refrigeration and transport of the device (69.0%). Just under half of participants reported that the dosing frequency was convenient (44.8%), and approximately one-third reported that handling the cap was inconvenient (31.0%). Obesity Awareness Participants provided reasons why they perceived obesity as a disease. These included a psychological problem causing an uncontrollable appetite (24.1%), an improvement in body weight and laboratory data post-treatment (10.3%), and an increase in the risk of other diseases (3.4%). Participants also commented on why they did not perceive obesity as a disease. These included constitution (20.7%), the absence of other diseases (10.3%), and the potential for body weight loss with effort (6.9%). Discussion Most study participants experienced body weight loss and improved appetite control during SURMOUNT-J. The use of tirzepatide was predominantly associated with changes in eating habits, but there was less influence on changes in exercise habits. Overall, 75.9% of participants expressed a willingness to continue drug therapy. Changes in eating behaviors that were initiated during the trial were maintained by just over half of the participants after the trial ended. The interviews provided some insights on obesity management needs according to the study participants, including potential unmet needs for personalized diet and exercise therapy, and improved information on obesity-related risks and departments that offer obesity treatment. Regarding transferability, the characteristics of the participants in SURMOUNT-J were nearly identical in terms of age, sex ratio, and mean body weight at enrollment to the characteristics of the participants in the present study [24]. This suggests similarity between participants in this study and those in SURMOUNT-J for these particular variables. Participants reported changes in their eating habits during SURMOUNT-J. These changes included a loss of appetite because of tirzepatide, changes in food preferences, an intentional increase in the amount of vegetables eaten, and the selection of meals according to a calorie table. After the trial ended, 51.7% of participants maintained the changes in eating behavior that were initiated during the trial. This included a change in their sense of taste and a lack of desire for greasy foods, suggesting that some medications can trigger changes in eating habits. Studies of other body weight loss drugs, such as semaglutide, also have been reported to change eating habits, including fewer food cravings, better eating control/less emotional eating, and changes in food preference [26, 27]. In the present study, a small proportion of participants (10.3%) reported that they no longer experienced joy when eating during the trial, which could potentially have a negative impact on their quality of life. Some participants reported lighter body movements (51.7%) and changes in exercise habits (37.9%) during the trial. When undertaking activities of daily life such as climbing stairs, these participants noticed that their body felt lighter and that they felt less fatigued. Such experiences were considered to be very beneficial. Importantly, while some participants (37.9%) reported changes to their exercise habits during the trial, 44.8% said that they were unable to maintain exercise habits after the trial ended. The use of tirzepatide appears to be associated with changes in eating habits rather than changes in exercise habits, indicating that it may be difficult to induce behavioral changes in exercise. Many participants thought that general guidance on exercise was not useful for them and expressed their preference for individualized guidance. This may reflect a potential unmet need for healthcare providers to prescribe exercise therapy at medical facilities. Some participants were not able to maintain their body weight loss after the trial ended and experienced a rebound in their body weight. Some participants (13.8%) relied on alternative methods, such as esthetic treatments, to try to prevent regaining the body weight lost during the trial. Some participants also considered obesity treatment as a beauty treatment. The difficulty that some participants experienced in maintaining body weight loss after the trial ended highlights the importance of recognizing obesity as a disease and providing patients with the appropriate treatment. Some participants reported seeking information on places where they could receive obesity treatment and the need to be provided with information regarding obesity-related risks. This suggests that there is room for improvement in the information provided by healthcare providers to patients about obesity and the associated risks, as well as treatment options [28]. While many participants had no concerns about entering a facility called “Obesity Clinic,” some did. Thus, when naming departments or clinics, it may be beneficial to consider names that reduce stigma, are accessible, avoid patient discomfort and self-consciousness, and do not cause psychological hesitance [29]. It is also important to raise awareness in society about obesity so that patients undergoing treatment for the disease do not feel stigmatized. The interviews revealed interesting insights on participant-preferred communication with and monitoring by healthcare providers. Some participants hoped their healthcare providers would manage the safety of their treatment and clinical data. Some participants were concerned with excessive body weight loss and wanted a healthcare provider to check whether their body weight loss was occurring in a safe and healthy manner. Although they had a positive view of body weight loss, some participants had anxiety around major changes they experienced with body weight loss, such as adverse reactions to treatment or unfavorable events caused by their body weight loss. These findings suggest that healthcare providers should always keep in mind the need to support patients, work to understand their patient’s feelings, and strive to provide effective communication and monitoring, thus potentially reducing patient anxiety. A patient experience study was conducted following the conclusion of SURMOUNT-4, a phase 3 trial of the efficacy and safety to tirzepatide in participants living with obesity or in those who were overweight with ≥ 1 weight-related comorbidity in the USA [25]. Similar findings between the SURMOUNT-4 exit interview study and the present study included the reported benefits during treatment (e.g., appetite decrease, increased positivity), that most participants wanted to continue tirzepatide (91% and 76%, respectively), and that most participants found the injection device easy to use (98% and 72%, respectively) [25]. Key differences were that the present study found that changes in dietary habits were maintained after discontinuing tirzepatide, but exercise habits were not. Additionally, the present study clarified the need for weight management after stopping tirzepatide treatment. Aspects regarding the post-discontinuation period, which were not investigated in the SURMOUNT-4 exit interview study, provided new insights from this study. This study has several limitations that should be considered when interpreting the results. We did not use theoretical sampling, which assumes theoretical saturation. Rather, we used convenience sampling for participant recruitment. Thus, theoretical saturation could not be confirmed. The participants in the present study have some similar characteristics to those of SURMOUNT-J, but they are not representative of the participants in SURMOUNT-J in all aspects. It was assumed that participants would have a recall bias, so a pre-survey was conducted to encourage prior recall. Study participants were thought to be highly motivated to participate in clinical trials. As such, they may not be representative of people with obesity in the real-world environment. Additionally, the results may have been biased given that the present study only included participants who had completed tirzepatide treatment, meaning that those who discontinued treatment were not represented. Participants in this study were familiar with the Internet, suggesting the possibility of selection bias. During SURMOUNT-J, participants were advised to avoid leaving home as the clinical trial period overlapped with the COVID-19 pandemic. It is assumed that this resulted in the loss of opportunities to eat out and to exercise, which likely affected the diet and exercise regimen of participants during the trial. Finally, the sample size is small, and studies in larger populations will be of value. To gain a more holistic understanding of the patient experience with tirzepatide treatment, future studies are warranted to incorporate a comprehensive evaluation that includes not only positive experiences but also potential negative experiences and psychological outcomes. Furthermore, conducting studies with larger patient populations, including quantitative approaches, could allow for a more appropriate examination of the differences in treatment experiences between patients who maintained their post-treatment weight and those who regained weight. Conclusion This study used web-based interviews to explore participant experience both during and after SURMOUNT-J in which participants received tirzepatide treatment for 72 weeks. Participants who received tirzepatide treatment reported that they were able to maintain their changes in eating behavior but not exercise habits. Notably, three-quarters of participants expressed willingness to continue drug therapy for obesity disease treatment. This study highlights the importance of providing information to people with obesity disease and connecting them with appropriate medical interventions, including treatment. Supplementary Information Below is the link to the electronic supplementary material.Supplementary file1 (PDF 1234 KB) Supplementary file1 (PDF 1234 KB)